WendyStockMD

PubMed

• Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
  Barr, P. M., Barr, P. M., Barr, P. M., Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Na...> ;Blood. 2024 Apr 18
• Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
  Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel, Peter A Riedell, Olatoyosi Odenike, Wendy Stock, Richard A Larson, Michael R Bishop, E...> ;Haematologica. 2024 Apr 11
• Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
  Xin Huang, Yizhen Li, Jingliao Zhang, Lei Yan, Huanbin Zhao, Liang Ding, Sheetal Bhatara, Xu Yang, Satoshi Yoshimura, Wenjian Yang, Seth E Karol, Hiroto Inaba, Charles...> ;Cancer Cell. 2024 Apr 8
• Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
  Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, Caner Saygin, Mariam T Nawas, Michael W Drazer, Adam S DuVall, Satyajit Kosuri, Michael J Thirman, Olatoyosi Ode...> ;Leukemia & Lymphoma. 2024 Mar 5
• 2 citations
  A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
  Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
• Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
  Johnston, H., Youshanlouei, H., Osei, C., Patel, A., DuVall, A., Wang, P., Wanjari, P., Segal, J., Venkataraman, G., Cheng, J., Gurbuxani, S., Lager, A., Fitzpatrick, ...> ;Blood Advances. 2024 Jan 9
• Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
  Geoffrey Parriott, Emma Hegermiller, Rosemary E Morman, Cameron Frank, Caner Saygin, Wendy Stock, Elizabeth T Bartom, Barbara L Kee> ;Leukemia. 2024 Mar 1
• 1 citations
  Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators.
  Kelly R Barnett, Robert J Mobley, Jonathan D Diedrich, Brennan P Bergeron, Kashi Raj Bhattarai, Alexander C Monovich, Shilpa Narina, Wenjian Yang, Kristine R Crews, Ch...> ;Cell Genomics. 2023 Dec 13
• Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
  Rafael Madero-Marroquin, Adam S DuVall, Caner Saygin, Peng Wang, Sandeep Gurbuxani, Richard A Larson, Wendy Stock, Anand Ashwin Patel> ;British Journal of Haematology. 2024 Apr 1
• 2 citations
  Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
  Farhad Ravandi, Asad Bashey, James Foran, Wendy Stock, Raya Mawad, Nicholas Short, Musa Yilmaz, Hagop Kantarjian, Olatoyosi Odenike, Anand Patel, Raman Garcha, William...> ;Blood Advances. 2023 Nov 14
• Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
  Uma Borate, Fei Yang, Richard Press, Amy S Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C Pavlick, Luke Juckett, Brianna Norris, Taylor Bu...> ;Blood Advances. 2023 Oct 24
• 1 citations
  A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America.
  Juan Rangel-Patiño, Yu Ling Lee-Tsai, Victor Itaí Urbalejo-Ceniceros, Maria Elena Monserrat Luna-Perez, Karla Adriana Espinosa-Bautista, Lauro Fabian Amador, Álvaro Ca...> ;Blood Advances. 2023 Sep 26
• Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
  Bhavana Bhatnagar, Jessica Kohlschmidt, Shelley J Orwick, Daelynn R Buelow, Sydney Fobare, Christopher C Oakes, Jonathan E Kolitz, Geoff Uy, Wendy Stock, Bayard L Powe...> ;Blood Advances. 2023 Aug 22
• Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
  Bhavana Bhatnagar, Jessica Kohlschmidt, Shelley J Orwick, Daelynn R Buelow, Sydney Fobare, Christopher C Oakes, Jonathan E Kolitz, Geoff Uy, Wendy Stock, Bayard L Powe...> ;Blood Advances. 2023 Aug 22
• 2 citations
  Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
  Caner Saygin, Giorgia Giordano, Kathryn Shimamoto, Bart Eisfelder, Anika Thomas-Toth, Girish Venkataraman, Vijayalakshmi Ananthanarayanan, Tiffaney L Vincent, Adam DuV...> ;Clinical Cancer Research. 2023 Aug 15
• 1 citations
  Influence of participant and reviewer characteristics in application scores for a hematology research training program.
  Sara K Vesely, Allison King, Emily Vettese, John G Heller, Adam Cuker, Cecelia Calhoun, Wendy Stock, Morgan Homer, Josel Fritz, Lillian Sung> ;Blood Advances. 2023 Aug 8
• Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells.
  Lauren Rowland, Brandon Smart, Anthony Brown, Gino M Dettorre, Yoshihiro Gocho, Jeremy Hunt, Wenjian Yang, Satoshi Yoshimura, Noemi Reyes, Guoqing Du, August John, Dyl...> ;Bio-Protocol. 2023 Aug 5
• 1 citations
  Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures.
  Kelly R Barnett, Robert J Mobley, Jonathan D Diedrich, Brennan P Bergeron, Kashi Raj Bhattarai, Wenjian Yang, Kristine R Crews, Christopher S Manring, Elias Jabbour, E...> ;Biorxiv. 2023 Jul 13
• Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding.
  Amani Alqahtani, Diala Alhousari, Amir Ali, George Yaghmour, Etan Orgel, Emily Curran, Wendy Stock, Deepa Bhojwani, Houda Alachkar> ;Expert Opinion on Drug Metabolism & Toxicology. 2023 Jul 6
• 1 citations
  Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
  Guanghao Liang, Linchen Wang, Qiancheng You, Kirk Cahill, Chuanyuan Chen, Wei Zhang, Noreen Fulton, Wendy Stock, Olatoyosi Odenike, Chuan He, Dali Han> ;Advanced Science. 2023 Aug 1
• 1 citations
  Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
  Vu H Duong, Amy S Ruppert, Alice S Mims, Uma Borate, Eytan M Stein, Maria R Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L Arellano, Gary J Schiller, Reb...> ;Cancer. 2023 Aug 1
• 2 citations
  Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
  Satoshi Yoshimura, John C Panetta, Jianzhong Hu, Lie Li, Yoshihiro Gocho, Guoqing Du, Akihiro Umezawa, Seth E Karol, Ching-Hon Pui, Charles G Mullighan, Marina Konople...> ;Leukemia. 2023 Jun 1
• 14 citations
  Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
  Krzysztof Mrózek, Jessica Kohlschmidt, James S Blachly, Deedra Nicolet, Andrew J Carroll, Kellie J Archer, Alice S Mims, Karilyn T Larkin, Shelley Orwick, Christopher ...> ;Leukemia. 2023 Apr 1
• Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
  Kashi Raj Bhattarai, Robert J Mobley, Kelly R Barnett, Daniel C Ferguson, Baranda S Hansen, Jonathan D Diedrich, Brennan P Bergeron, Wenjian Yang, Kristine R Crews, Ch...> ;Medrxiv. 2023 Feb 11
• 3 citations
  Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
  Ibrahim Aldoss, Bijal D Shah, Jae H Park, Lori Muffly, Aaron C Logan, Patrick Brown, Wendy Stock, Elias J Jabbour> ;American Journal of Hematology. 2023 Apr 1
• Join now to see all

Journal Articles

• Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia  
  Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature

Abstracts/Posters

• Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelody...
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression
  Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Adult Clinical Malignant Hematology 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• New Data and Paradigms in ALL: Insights and Applications 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Adult Clinical Malignant Hematology 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Rela... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus o... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Transitions From the Adult Perspective 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosomeâ€positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all

Other

• Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL 
  Wendy Stock, MD, Blood
  https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
  UpToDate, Wolters Kluwer Health - 2013-04-03
• Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL 
  Wendy Stock, MD, Blood
  https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
  UpToDate, Wolters Kluwer Health - 2012-02-07
• Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL 
  Wendy Stock, MD, Blood
  https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
  UpToDate, Wolters Kluwer Health - 2012-09-10
• Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL 
  Wendy Stock, MD, Blood
  https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
  UpToDate, Wolters Kluwer Health - 2013-01-28
• Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL 
  Wendy Stock, MD, Blood
  https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
  UpToDate, Wolters Kluwer Health - 2012-03-28
• Join now to see all